Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss.
We have investigated the effect of 0.001 mg/kg delta(8)-tetrahydrocannabinol (THC) on food consumption, cognitive function, and neurotransmitters in mice. Sabra mice were treated with vehicle, THC, or THC+CB1 antagonist (SR141716A). The mice were fed for 2.5 h a day for 9 or 50 days. In the 9-day schedule, THC-treated mice showed a 16% increase in food intake compared with controls (P<.001). This effect was reversed by the antagonist (P<.01). In the long-term schedule a 22% increase in intake (P<.05) was recorded. During the course of the 9- and 50-day experimental protocol, all mice lost about 20% and 10% of their original weight, respectively, to reach approximately the same weights, which were not significantly different between the different treatment groups. In addition, THC caused an increase in activity (P<.05). Cognitive function showed a tendency to improve (P<.06) in the THC-treated mice, which was reversed by the antagonist for Days 4 and 5 of the maze (P<.01, and P<.05, respectively). Significant decreases in dopamine and serotonin (5-HT) levels were found both in the hypothalamus (P<.01) and the hippocampus (P<.01, P<.05), respectively, while norepinephrine (NE) levels showed tendency to increase in both the hypothalamus and hippocampus. Delta(8)-THC increased food intake significantly more (P<.05) than did delta(9)-THC, while performance and activity were similar. Thus, delta(8)-THC (0.001 mg/kg) caused increased food consumption and tendency to improve cognitive function, without cannabimimetic side effects. Hence, a low dose of THC might be a potential therapeutic agent in the treatment of weight disorders.
Avraham
Yosefa
Y
Department of Human Nutrition and Metabolism, Hebrew University-Hadassah Medical School, POB 12272, Jerusalem 91120, Israel. yosefa@md2.huji.ac.il
Ben-Shushan
Dikla
D
Breuer
Aviva
A
Zolotarev
Olga
O
Okon
Avital
A
Fink
Nir
N
Katz
Vered
V
Berry
Elliot M
EM
D000818:Animals; D013759:Dronabinol / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D004435:Eating / Q000187:drug effects* / Q000502:physiology; D005260:Female; D018782:Maze Learning / Q000187:drug effects / Q000502:physiology; D051379:Mice; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D000077285:Rimonabant; D015431:Weight Loss / Q000187:drug effects* / Q000502:physiology
D018377:Neurotransmitter Agents; D010880:Piperidines; D011720:Pyrazoles; C009411:delta(6)-tetrahydrocannabinol-7-oic acid; D013759:Dronabinol; D000077285:Rimonabant